← Back to Search

Glucagon-like peptide-1 receptor agonist

Cohort B for Diabetes

Phase 1
Waitlist Available
Led By Hanmi Clinical
Research Sponsored by Hanmi Pharmaceutical Company Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 weeks
Awards & highlights

Study Summary

A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus

Eligible Conditions
  • Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK profile of acetaminophen
Secondary outcome measures
Glucose metabolism
Safety and tolerability

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort CExperimental Treatment1 Intervention
The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg
Group II: Cohort BExperimental Treatment2 Interventions
The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg
Group III: Cohort AExperimental Treatment2 Interventions
The weekly treatment of the 6 mg HM11260C or placebo will be maintained
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exenatide
FDA approved
Liraglutide
FDA approved
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Hanmi Pharmaceutical Company LimitedLead Sponsor
190 Previous Clinical Trials
61,061 Total Patients Enrolled
Hanmi ClinicalPrincipal InvestigatorCalifornia, United States
3 Previous Clinical Trials
165 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
2013. "A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02059564.
All > Gestational Diabetes > Victoza
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top